Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Natiya E. Robinson"'
Autor:
Tracy Lu, Vanessa L. Norman, Lee R. Cavedine, Kayla A. Stehle, Steven M. Garner, Natiya E. Robinson, Alyssa M. Croff, Jesse J. Parry, Victoria V. McBain, Kristin C. Dempsey, Joseph T. Murphy, Charles R. Wageman, Brogan A. Epkins, Alastair J. King
Publikováno v:
Cancer Research. 79:4245-4245
High-throughput, cell-based drug screening platforms are essential to guiding drug discovery programs and can rapidly generate large amounts of pharmacological information about a candidate drug. Drug response data combined with genomic and phenotypi
Autor:
Alastair J. King, Natiya E. Robinson, Kayla A. Stehle, Steven M. Garner, Jesse J. Parry, Vanessa L. Norman, Kristin C. Dempsey, Joseph W. Murphy, Charles R. Wageman, Alyssa M. Croff, Lee R. Cavedine, Tracy Lu, Brogan A. Epkins, Victoria V. McBain
Publikováno v:
Cancer Research. 79:2073-2073
Oncology drugs with clinical utility for the treatment of breast cancer span a wide range of different mechanisms and cancer type profiles. Anti-cancer therapies have come a long way from the early use of broad spectrum, cytotoxic agents, with mechan
Autor:
Natiya E. Robinson, Alyssa M. Croff, Vanessa L. Norman, Alastair J. King, Brogan A. Epkins, Lee R. Cavedine, Steven M. Garner, Jesse J. Parry, Kristin C. Dempsey, Charles R. Wageman, Usha Warrior
Publikováno v:
Cancer Research. 78:2260-2260
Using drug response data, generated by the OncoPanelTM cell-based profiling service, we investigated the differences between traditional and normalized growth rate inhibition (GR) metrics in drug sensitivity classification and predictive genomic biom
Autor:
Usha Warrior, Timothy J. Sindelar, Natiya E. Robinson, Vanessa L. Norman, Kristin C. Dempsey, Brogan A. Epkins, Alastair J. King, Charles R. Wageman, Lee R. Cavedine, Steven M. Garner, Jesse J. Parry, Alyssa M. Croff
Publikováno v:
Cancer Research. 78:1391-1391
Given the importance and significance of targeting mutations and epigenetic modification in cancer therapy, we sought to expand on our ability to test drugs with epigenetic modulatory abilities by increasing the exposure time of drugs against cell li